NEOADJUVANT MK-3475(KEYNOTE-756)

Breast - NEOADJUVANT

NEOADJUVANT MK-3475(KEYNOTE-756)

Objective

A Randomized, Double-Blind, Study of Pembrolizumab vs. Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage ER+/HER2– Breast Cancer

Principal Investigator(s)
Swati Sikaria, MD
Reva Bash, MD

Clinical Trial Categories

  • Cedars-Sinai Clinical Trials